Hepatitis B Virus News and Research

RSS

New Jefferson Hepatitis C Center

Thomas Jefferson University Hospital recently opened its new Jefferson Hepatitis C Center, one of only a few comprehensive, multidisciplinary centers dedicated to the study of hepatitis C virus and hepatic disease in the Pennsylvania, New Jersey and Delaware tri-state area.

14 May 2012

Viewpoints: Two views on how to fight obesity; Tough choices for big business on health costs

Forgive us if we don't cheer at the prospect of adding 32 million to the total number of Americans who are dozens of pounds too heavy, a count that stood in 2010 at 78 million.

11 May 2012

Treatable infections responsible for nearly 2M cases of cancer globally each year, study suggests

"Bacteria, viruses and parasites cause around two million cases of cancer in the world each year, experts believe," the Press Association/Guardian reports. According to the news service, "Scientists carried out a statistical analysis of cancer incidence to calculate that around 16 percent of all cancers diagnosed in 2008 were infection-related," and "the proportion of cancers linked to infection was three times higher in developing countries than in developed ones."

10 May 2012

Inovio first quarter total revenue decreases to $1.7 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2012.

10 May 2012

One in six cancer cases worldwide related to preventable or curable infections

New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.

9 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

Interferon linked with increased risk of depression in HCV patients

There's a high rate of depression among patients with hepatitis C, but a standard treatment for the disease includes a drug, interferon, that can cause depression.

2 May 2012

Severe fibrosis increases early atherosclerosis risk in patients with chronic HCV-1 infection

Italian researchers report that severe fibrosis increases the early atherosclerosis risk in patients with genotype 1 chronic hepatitis C virus (HCV) infection. A second study found that fatty liver disease also increases risk of developing atherosclerosis at an earlier period. Both studies appear in the May issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

25 Apr 2012

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

New data from a descriptive sub-analysis of patients with compensated liver cirrhosis show that up to 43 percent of genotype-1a (GT1a) and up to 71 percent of GT1b hepatitis C virus (HCV) patients achieved sustained viral response (SVR12). SVR12 has been highly correlated with SVR24, which is a recognized indicator of viral cure.

20 Apr 2012

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.

20 Apr 2012

EASL publishes new clinical practice guideline on ALD

EASL today announced the publication of a new clinical practice guideline (CPG) in the area of Alcoholic Liver Disease (ALD), bringing the number of CPGs published to date to eight.

19 Apr 2012

Bristol-Myers Squibb, Janssen expand TMC435, BMS-986094 clinical collaboration agreement

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Janssen R&D Ireland has broadened its clinical collaboration agreement with Bristol-Myers Squibb Company.

19 Apr 2012

Key data from Boehringer Ingelheim's hepatitis C virus clinical trial programme

Key data from Boehringer Ingelheim's hepatitis C virus (HCV) clinical trial programme, HCVerso, focusing on interferon-free treatment, has been selected for inclusion in the official European Association for the Study of the Liver (EASL) press office activities.

6 Apr 2012

Results from Abbott’s multiple interferon-free Phase 2 HCV studies to be presented at ILC 2012

Abbott will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.

5 Apr 2012

Scripps Florida scientists to create new screening tests for HCV treatment discovery

Scientists from the Florida campus of The Scripps Research Institute have been awarded just over $1 million from the National Institutes of Health for a three-year study to develop new high-throughput screening tests to find compounds that disable a protein essential to hepatitis C virus (HCV) replication.

5 Apr 2012

Hepatitis B Virus News and Research

New Jefferson Hepatitis C Center

Viewpoints: Two views on how to fight obesity; Tough choices for big business on health costs

Treatable infections responsible for nearly 2M cases of cancer globally each year, study suggests

Inovio first quarter total revenue decreases to $1.7 million

One in six cancer cases worldwide related to preventable or curable infections

Alnylam first quarter revenues decrease to $20.6 million

Array BioPharma third quarter revenue increases to $19.1M

Interferon linked with increased risk of depression in HCV patients

Severe fibrosis increases early atherosclerosis risk in patients with chronic HCV-1 infection

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

EASL publishes new clinical practice guideline on ALD

Bristol-Myers Squibb, Janssen expand TMC435, BMS-986094 clinical collaboration agreement

Key data from Boehringer Ingelheim's hepatitis C virus clinical trial programme

Results from Abbott’s multiple interferon-free Phase 2 HCV studies to be presented at ILC 2012

Scripps Florida scientists to create new screening tests for HCV treatment discovery

Scientists discover new anti-HCV antibodies

Study: 20.1M individuals infected with HEV across 9 world regions

Chemists produce first high resolution structure of HCV viral RNA-inhibitor complex

GenMark Diagnostics fourth quarter revenues increase to $2.0 million

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News